Logo image of XTNT

XTANT MEDICAL HOLDINGS INC (XTNT) Stock Fundamental Analysis

USA - NYSEARCA:XTNT - US98420P3082 - Common Stock

0.638 USD
+0.01 (+1.71%)
Last: 9/25/2025, 8:09:34 PM
0.632 USD
-0.01 (-0.94%)
After Hours: 9/25/2025, 8:09:34 PM
Fundamental Rating

2

Taking everything into account, XTNT scores 2 out of 10 in our fundamental rating. XTNT was compared to 190 industry peers in the Health Care Equipment & Supplies industry. XTNT has a bad profitability rating. Also its financial health evaluation is rather negative. XTNT is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year XTNT has reported negative net income.
XTNT had a negative operating cash flow in the past year.
XTNT had negative earnings in 4 of the past 5 years.
XTNT had negative operating cash flow in 4 of the past 5 years.
XTNT Yearly Net Income VS EBIT VS OCF VS FCFXTNT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M

1.2 Ratios

XTNT has a Return On Assets of -12.51%. This is comparable to the rest of the industry: XTNT outperforms 57.89% of its industry peers.
Looking at the Return On Equity, with a value of -27.33%, XTNT is in line with its industry, outperforming 58.42% of the companies in the same industry.
Industry RankSector Rank
ROA -12.51%
ROE -27.33%
ROIC N/A
ROA(3y)-10.3%
ROA(5y)-11.34%
ROE(3y)-20.61%
ROE(5y)-25.18%
ROIC(3y)N/A
ROIC(5y)N/A
XTNT Yearly ROA, ROE, ROICXTNT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 200

1.3 Margins

The Gross Margin of XTNT (58.18%) is comparable to the rest of the industry.
In the last couple of years the Gross Margin of XTNT has declined.
XTNT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 58.18%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.35%
GM growth 5Y-2.41%
XTNT Yearly Profit, Operating, Gross MarginsXTNT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

More info and screens

2

2. Health

2.1 Basic Checks

XTNT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for XTNT has been increased compared to 1 year ago.
Compared to 5 years ago, XTNT has more shares outstanding
The debt/assets ratio for XTNT is higher compared to a year ago.
XTNT Yearly Shares OutstandingXTNT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
XTNT Yearly Total Debt VS Total AssetsXTNT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

2.2 Solvency

Based on the Altman-Z score of -1.32, we must say that XTNT is in the distress zone and has some risk of bankruptcy.
XTNT has a Altman-Z score (-1.32) which is in line with its industry peers.
XTNT has a Debt/Equity ratio of 0.51. This is a neutral value indicating XTNT is somewhat dependend on debt financing.
XTNT's Debt to Equity ratio of 0.51 is on the low side compared to the rest of the industry. XTNT is outperformed by 61.05% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.51
Debt/FCF N/A
Altman-Z -1.32
ROIC/WACCN/A
WACC9.16%
XTNT Yearly LT Debt VS Equity VS FCFXTNT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 2.34 indicates that XTNT has no problem at all paying its short term obligations.
XTNT has a Current ratio (2.34) which is comparable to the rest of the industry.
XTNT has a Quick Ratio of 1.03. This is a normal value and indicates that XTNT is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.03, XTNT is doing worse than 75.26% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.34
Quick Ratio 1.03
XTNT Yearly Current Assets VS Current LiabilitesXTNT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

4

3. Growth

3.1 Past

XTNT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -100.00%.
XTNT shows a strong growth in Revenue. In the last year, the Revenue has grown by 28.44%.
XTNT shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 12.64% yearly.
EPS 1Y (TTM)-100%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%166.67%
Revenue 1Y (TTM)28.44%
Revenue growth 3Y28.5%
Revenue growth 5Y12.64%
Sales Q2Q%18.26%

3.2 Future

The Earnings Per Share is expected to grow by 27.75% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 3.31% on average over the next years.
EPS Next Y83%
EPS Next 2Y36.84%
EPS Next 3Y27.75%
EPS Next 5YN/A
Revenue Next Year10.6%
Revenue Next 2Y0.34%
Revenue Next 3Y3.31%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
XTNT Yearly Revenue VS EstimatesXTNT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M 80M 100M
XTNT Yearly EPS VS EstimatesXTNT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2019 2020 2023 2024 2025 2026 2027 0 -5 -10 -15 -20

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for XTNT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for XTNT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XTNT Price Earnings VS Forward Price EarningsXTNT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XTNT Per share dataXTNT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6 0.8

4.3 Compensation for Growth

XTNT's earnings are expected to grow with 27.75% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.84%
EPS Next 3Y27.75%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for XTNT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

XTANT MEDICAL HOLDINGS INC

NYSEARCA:XTNT (9/25/2025, 8:09:34 PM)

After market: 0.632 -0.01 (-0.94%)

0.638

+0.01 (+1.71%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-12 2025-08-12/bmo
Earnings (Next)11-10 2025-11-10/bmo
Inst Owners57.58%
Inst Owner Change-9.48%
Ins Owners14.69%
Ins Owner Change-0.26%
Market Cap83.14M
Analysts85
Price Target1.79 (180.56%)
Short Float %0.04%
Short Ratio0.59
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)34.64%
Min EPS beat(2)-30.72%
Max EPS beat(2)100%
EPS beat(4)1
Avg EPS beat(4)-8.66%
Min EPS beat(4)-56.86%
Max EPS beat(4)100%
EPS beat(8)3
Avg EPS beat(8)37.09%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.27%
Min Revenue beat(2)-2.85%
Max Revenue beat(2)3.39%
Revenue beat(4)2
Avg Revenue beat(4)-0.92%
Min Revenue beat(4)-6.52%
Max Revenue beat(4)3.39%
Revenue beat(8)6
Avg Revenue beat(8)4.72%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)42.86%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.25%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.68
P/FCF N/A
P/OCF N/A
P/B 1.89
P/tB 2.9
EV/EBITDA N/A
EPS(TTM)-0.04
EYN/A
EPS(NY)-0.02
Fwd EYN/A
FCF(TTM)-0.07
FCFYN/A
OCF(TTM)-0.04
OCFYN/A
SpS0.94
BVpS0.34
TBVpS0.22
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -12.51%
ROE -27.33%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 58.18%
FCFM N/A
ROA(3y)-10.3%
ROA(5y)-11.34%
ROE(3y)-20.61%
ROE(5y)-25.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.35%
GM growth 5Y-2.41%
F-Score2
Asset Turnover1.28
Health
Industry RankSector Rank
Debt/Equity 0.51
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 105.54%
Cap/Sales 3.7%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.34
Quick Ratio 1.03
Altman-Z -1.32
F-Score2
WACC9.16%
ROIC/WACCN/A
Cap/Depr(3y)93.26%
Cap/Depr(5y)102.58%
Cap/Sales(3y)2.72%
Cap/Sales(5y)2.97%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-100%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%166.67%
EPS Next Y83%
EPS Next 2Y36.84%
EPS Next 3Y27.75%
EPS Next 5YN/A
Revenue 1Y (TTM)28.44%
Revenue growth 3Y28.5%
Revenue growth 5Y12.64%
Sales Q2Q%18.26%
Revenue Next Year10.6%
Revenue Next 2Y0.34%
Revenue Next 3Y3.31%
Revenue Next 5YN/A
EBIT growth 1Y37.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year167.51%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-12.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y26.12%
OCF growth 3YN/A
OCF growth 5YN/A